AKRO
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Akero Therapeutics to be acquired by Novo Nordisk for up to $5.2 billionOct 9, 2025
- Akero Therapeutics announces Lancet publication of Phase 2b HARMONY trial showing 96 weeks of EFX treatment reduced liver fibrosis in pre-cirrhotic MASH patientsAug 15, 2025
- Akero Therapeutics and HistoIndex present new analyses from the Phase 2b HARMONY trial in oral and poster presentations at the EASL Congress 2025.May 11, 2025
- Akero Therapeutics presents Week 96 results from the Phase 2b SYMMETRY trial of Efruxifermin in patients with compensated cirrhosis caused by MASH, showing fibrosis improvement without worsening of MASH at the EASL Congress 2025.May 9, 2025
- Akero Therapeutics announces the publication of Phase 2b SYMMETRY trial results in the New England Journal of Medicine.May 9, 2025